A Delaware man is the first to take legal action against the manufacturer of a batch of a bone graft product that’s reported to have caused patients to contract tuberculosis post-surgery.

The lot of FiberCel, the product made by Delaware-based biotechnology company Aziyo Inc., included 154 units distributed across 20 states, and the company has recognized at least four patients who received FiberCel from that lot have developed tuberculosis.